Search Results for: Pharma: Other News to Note
-
Other News To Note
In addition to RA and Crohn's, the pharma may develop GLPG0634 in psoriasis, irritable bowel syndrome and lupus, mirroring the path by which the label on its blockbuster Humira (adalimumab) was expanded beyond RA...Helsinn Healthcare SA, of Lugano, Switzerland, and Vifor Pharma, of Villars-sur-Glane, Switzerland, signed an exclusive license and distribution agreement for netupitant-palonosetron fixed-dose combination, an investigational Helsinn product for chemotherapy-induced nausea and vomiting -
Other News To Note
for the Brisbane, Australia-based company's Diversity Scanning Array (DSA) and Versatile Assembly on Stable Templates (VAST) technologies in a deal worth up to $240 million in milestones, plus other payments...to conduct a review of merger and acquisition opportunities. (See BioWorld Today, Feb. 1, 2013...It expects to launch the product in Canada, and a number of Central American, South American and Asian countries in 2014 and 2015 -
Other News To Note
Furiex inked the deal with Menarini in 2012, giving the Italian pharma firm rights to commercialize Priligy in Europe, most of Asia, Africa, Latin America and the Middle East...The refund was received to support research and clinical development of PBT2 for Huntington's and Alzheimer's diseases, as well as for other Prana research activities into Parkinson's disease and other neurological indications -
Other News To Note
NeoStem Inc., of New York, said it was awarded the second year of a two-year grant totaling $595,252 from the National Institute of Allergy and Infectious Diseases for the development of human, autologous, pluripotent very small embryonic-like (VSEL) stem cells as a countermeasure to radiation threats...In other news, SCT closed its previously announced private placement for gross proceeds of C$3.2 million (US$3.1 million -
Other News To Note
Clinigen Group plc, of Burton-on-Trent, UK, and Theravance Inc., of South San Francisco, entered an exclusive commercialization agreement in the European Union and certain other countries located in Europe for Vibativ (telavancin) in nosocomial pneumonia, including ventilator-associated pneumonia, known or suspected to be caused by methicillin-resistant Staphylococcus aureus, when other alternatives are not suitable...In other news, Elan said its Tysabri (natalizumab) restructuring transaction is -
Aiming for NDA, Trius Pads Coffers with $30M Offering
Beyond Pfizer, other big pharma firms also could be interested...The Gyrase B program has been funded largely under a National Institute of Allergy and Infectious Diseases contract, though a portion of proceeds from the public offering are expected to advance the compounds in investigational new drug application-enabling efforts this year...In other financings news -
Biotech Diaries: EcoR1 Surveys Investment Options at JPM
In addition to Kim, we were joined by a long-time friend and medical consultant who's helping to vet oncology assets...In contrast to most partnering discussions in small suites, that meeting was held in a large board room with a long conference table -
Other News To Note
The Merck expansion grants the big pharma further access to Adimab's technology to discover and optimize fully human antibody candidates, including potentially bispecific antibody candidates, across all disease areas...Altravax Inc., of Fargo, N.D., said it received two Advanced Technology Small Business Innovation Research grants from the National Institute of Allergy and Infectious Diseases for research on vaccines to prevent infection by dengue virus and to treat chronic hepatitis B. In recent -
Other News To Note
Under the agreement, Pepscan will use its CLIPS platform and other protein mimicry technologies to help discover new antibodies...to purchase up to 1 million shares, or about 1.06 percent of the company's outstanding stock, at a price of $161.25 per share, marking a 4.46 percent discount to the Dec. 27 closing price -
Biotechnology Company Deals With Other Biotechnology Companies: Nov. 1 - Dec. 20, 2012
to Firdapse, a drug in development for Lambert-Eaton myasthenic syndrome BioMarin agreed to invest $5M in Catalyst under a promissory note and note purchase agreement 11/1/12 Colby Pharmaceutical Co. (San Jose, Calif.) MannKind Corp. (Valencia, Calif.) $140 Deal for disease-specific antigen compounds and intra-lymph node injection (INLI) technologies from its MKC1106 cancer vaccine program Colby is paying up to $140M in up-front and milestone payments to MannKind, which also will receive tiered -
Other News To Note
Apexigen Inc., of Burlingame, Calif., signed a manufacturing supply agreement with Boehringer Ingelheim GmbH, of Ingelheim, Germany, under which the big pharma firm will provide cell line development with the high expression BI-HEX system, full process and method development, scale-up and clinical Phase I supply for APX005, a humanized monoclonal antibody designed to target CD40 for treating cancer...iBio Inc., of Newark, Del., said the National Institute of Allergy and Infectious Diseases awarded -
Other News To Note
Akela Pharma Inc., of Vancouver, British Columbia, said it applied for voluntary delisting from the Toronto Stock Exchange, citing an inability to maintain the continuous listing requirements...Its expenses related to the terminations will be $280,000 in the fourth quarter -
Other News To Note
CureVac GmbH, of Tuebingen, Germany, and the German Federal Research Institute for Animal Health, Friedrich-Loeffler-Institute, said mRNA vaccines based on the company's RNA technology platform have the potential to provide effective protection against infectious diseases...Erytech Pharma, of Lyon, France, said it entered a definitive agreement granting Orphan Europe, part of the Recordati Group, of Milano, Italy, exclusive rights for the commercialization and distribution of Graspa in acute -
Biotechnology Company Deals With Other Biotechnology Companies: Sept. 1 - Nov. 19, 2012
and strategic global markets Financial terms were not disclosed 9/12/12 Oxford BioMedica plc (Oxford, UK) Immune Design Corp. (Seattle) ND Master services deal to use Oxford BioMedica's expertise in lentiviral vector clinical development for Immune Design's therapeutic vaccine candidate for cancer and other chronic diseases Financial terms were not disclosed 9/28/12 QLT Inc. (Vancouver, British Columbia) Valeant Pharmaceuticals International Inc. (Montreal) $112.5 Sale of wet, age-related -
Other News To Note
Evotec AG, of Hamburg, Germany, and Haplogen GmbH, of Vienna, Austria, signed a collaboration agreement to discover and develop small molecules against viral infectious diseases...In other news, Orexo said the FDA accepted for review its new drug application for Zubsolv, a sublingual formulation of buprenorphine and naloxone, and set a PDUFA date of July l6, 2013 -
Other News To Note
IL-17 mediated signaling is known to induce the expression of cytokines and other effectors in a variety of immunological diseases such as psoriasis and chronic obstructive pulmonary disease...Ventrus has started to enroll in its second Phase III pivotal trial, with results expected early fourth quarter 2013, and assuming a successful outcome, expects to file an NDA late in the fourth quarter of 2013 with an anticipated PDUFA date at the end of 2014 -
Other News To Note
Alnylam Pharmaceuticals Inc., and Genzyme Corp., a unit of Sanofi SA, both of Cambridge, Mass., formed an alliance to develop and commercialize RNAi therapeutics targeting transthyretin for the treatment of transthyretin-mediated amyloidosis (ATTR) in Japan and other Asia-Pacific countries...PTC Therapeutics Inc., of Plainfield, N.J., received a $1 million grant award from the National Institute of Allergy and Infectious Diseases to discover antiviral agents for the treatment of dengue fever, a -
Other News To Note
Patients were randomized to three dose groups of intravenously administered ALX-0061 (1mg/kg every 4 weeks, 3mg/kg every 4 weeks and 6mg/kg every 8 weeks) or to placebo...LEO Pharma A/S, of Ballerup, Denmark, disclosed plans to establish five long-term, strategic research collaborations in Australia, France, Germany and the U.S -
Other News To Note
Horizon Pharma Inc., of Deerfield, Ill., said it expanded its sales force from 80 to 150 representatives to facilitate increased reach and frequency of calls on physicians for its lead product, Duexis (ibuprofen and famotidine), which is indicated for the relief of symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers -
Other News To Note
Curadev Pharma Private Ltd., of New Delhi, India, triggered a milestone payment from Endo Health Solutions, of Newark, Del., by advancing its oncology program to the next stage of development...Those include a $600,000 Small Business Innovation Research Phase 1 award from the National Institute of Allergy and Infectious Diseases (NIAID) to assess KL4 surfactant's ability to mitigate acute radiation to the lung...oncology-focused company and a Top 20 pharma firm, in which MAB will deliver a number of
Category
Current Filters
- xInfectious Diseases
Related Keywords
Categories
- x BioWorld Today (443)
- x BioWorld International (91)
- x BioWorld Insight (6)
- x Bio Perspectives (2)
- x BioWorld Snapshots (1)
- x State of the Industry Report (1)